Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant

被引：0
|
作者：
Grace Chen
Ronald Lee
Astrid-Maria Højer
Jeppe Klint Buchbjerg
Michael Serenko
Zhen Zhao
机构：
[1] Takeda Development Center Americas,Clinical Pharmacology
[2] H. Lundbeck A/S,Pharmacovigilance
[3] Takeda Development Center Americas,Statistics
[4] Takeda Development Center Americas,undefined
来源：
Clinical Drug Investigation | 2013年 / 33卷
关键词：
Omeprazole; Fluconazole; Ketoconazole; Bupropion; Major Depressive Disorder Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：727 / 736
页数：9
相关论文
共 50 条
  • [41] Lu AA21004, a Novel Multi-target Drug, Displays Anxiolytic- and Antidepressant-Like Effects in Multiple Preclinical Assays
    Bisulco, Stephanie
    Miller, Silke
    Moore, Nicholas A.
    Mork, Arne
    Patel, Jignesh G.
    Poon, Patrick
    Sanchez, Connie
    Schnelker, Joanna H.
    Smith, Daniel G.
    Hogg, Sandra
    BIOLOGICAL PSYCHIATRY, 2009, 65 (08) : 108S - 108S
  • [42] The in vitro Proflie of Lu AA21004, a Novel Multi-Target Drug for the Treatment of Mood Disorders
    Stensbol, Tine B.
    Frederiksen, Kristen
    Zhong, Huailing
    Bang-Andersen, Benny
    BIOLOGICAL PSYCHIATRY, 2009, 65 (08) : 79S - 79S
  • [43] Pharmacological profile of Lu AA21004, a novel multi-target drug for the treatment of mood disorders
    Mork, A.
    Brennum, L. T.
    Fallon, S.
    Bisulco, S.
    Frederiksen, K.
    Bang-Andersen, B.
    Lassen, A. B.
    Zhong, H.
    Sanchez, C.
    Stensbol, T. B.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S439 - S439
  • [44] Lu AA21004, a novel antidepressant, modulates neurotransmitter levels and theta oscillations, and exerts pro-cognitive effects in rats
    Arbell, M.
    Diaz, M. C.
    Morales, N.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S407 - S408
  • [45] Preclinical characterisation of the novel antidepressant Lu AA21004: key role for the 5-HT3 receptors blockade
    Haddjeri, N.
    Etievant, A.
    Ebert, B.
    Sanchez, C.
    Betry, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S376 - S377
  • [46] The Clinical Pharmacokinetics of Lu AA21004 and its Major Metabolite in Healthy Young Volunteers
    Areberg, Johan
    Sogaard, Birgitte
    Hojer, Astrid-Maria
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2012, 111 (03) : 198 - 205
  • [47] A randomised, double-blind, placebo-controlled, active-referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients
    Katona, C.
    Hansen, T.
    Olsen, C. K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S258 - S259
  • [48] EFFECT OF FORMULATION AND FOOD ON THE PHARMACOKINETICS OF LU AA21004 IN HEALTHY SUBJECTS.
    Mayer, M.
    Xie, J.
    Serenko, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S69 - S70
  • [49] In Vivo Effects of the Multi-Target Drug Lu AA21004: A Novel Potential Treatment for Mood Disorders
    Mork, Arne
    Brennum, Lise T.
    Fallon, Shaun M.
    Lassen, Anders B.
    Sanchez, Connie
    Stensbol, Tine B.
    Hogg, Sandra
    BIOLOGICAL PSYCHIATRY, 2009, 65 (08) : 73S - 73S
  • [50] Prevention of relapse in adult patients with generalised anxiety disorder after response to the multimodal psychotropic agent Lu AA21004
    Baldwin, D. S.
    Loft, H.
    Florea, I.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S358 - S359
12345